Molecular Partners AG
SIX:MOLN

Watchlist Manager

Molecular Partners AG

SIX:MOLN

Watchlist

Dividends

Price: 4.85 CHF 0.73% Market Closed

Market Cap: 178.8m CHF

Have any thoughts about
Molecular Partners AG?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US		Fubotv Inc NYSE:FUBO	Media
US		Bank of America Corp NYSE:BAC	Banking
US		Palantir Technologies Inc NYSE:PLTR	Technology
US	C	C3.ai Inc NYSE:AI	Technology
US		Uber Technologies Inc NYSE:UBER	Road & Rail
CN		NIO Inc NYSE:NIO	Automobiles
US		Fluor Corp NYSE:FLR	Construction
US		Jacobs Engineering Group Inc NYSE:J	Professional Services
US		TopBuild Corp NYSE:BLD	Consumer products
US		Abbott Laboratories NYSE:ABT	Health Care
US		Chevron Corp NYSE:CVX	Energy
US		Occidental Petroleum Corp NYSE:OXY	Energy
US		Matrix Service Co NASDAQ:MTRX	Construction
US		Automatic Data Processing Inc NASDAQ:ADP	Technology
US		Qualcomm Inc NASDAQ:QCOM	Semiconductors
US		Ambarella Inc NASDAQ:AMBA	Semiconductors

Add Price Alert

Price Target:

Last Price: 4.85 CHF

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

MOLN Alert

Molecular Partners AG

4.85

+0.035 (+0.73%)

52 Week Range	3.17 9.3
Price Target

We'll email you a reminder when the closing price reaches CHF.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Fubotv Inc NYSE:FUBO	US
	Bank of America Corp NYSE:BAC	US
	Palantir Technologies Inc NYSE:PLTR	US
C	C3.ai Inc NYSE:AI	US
	Uber Technologies Inc NYSE:UBER	US
	NIO Inc NYSE:NIO	CN
	Fluor Corp NYSE:FLR	US
	Jacobs Engineering Group Inc NYSE:J	US
	TopBuild Corp NYSE:BLD	US
	Abbott Laboratories NYSE:ABT	US
	Chevron Corp NYSE:CVX	US
	Occidental Petroleum Corp NYSE:OXY	US
	Matrix Service Co NASDAQ:MTRX	US
	Automatic Data Processing Inc NASDAQ:ADP	US
	Qualcomm Inc NASDAQ:QCOM	US
	Ambarella Inc NASDAQ:AMBA	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Molecular Partners AG

What unique competitive advantages
does Molecular Partners AG hold over its rivals?

What risks and challenges
does Molecular Partners AG face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Molecular Partners AG.

What unique competitive advantages
does Molecular Partners AG hold over its rivals?

What risks and challenges
does Molecular Partners AG face in the near future?

Has there been any significant insider trading activity
in Molecular Partners AG recently?

Summarize the latest earnings call
of Molecular Partners AG.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Molecular Partners AG.

Provide P/S
for Molecular Partners AG.

Provide P/E
for Molecular Partners AG.

Provide P/OCF
for Molecular Partners AG.

Provide P/FCFE
for Molecular Partners AG.

Provide P/B
for Molecular Partners AG.

Provide EV/S
for Molecular Partners AG.

Provide EV/GP
for Molecular Partners AG.

Provide EV/EBITDA
for Molecular Partners AG.

Provide EV/EBIT
for Molecular Partners AG.

Provide EV/OCF
for Molecular Partners AG.

Provide EV/FCFF
for Molecular Partners AG.

Provide EV/IC
for Molecular Partners AG.

Show me price targets
for Molecular Partners AG made by professional analysts.

What are the Revenue projections
for Molecular Partners AG?

How accurate were the past Revenue estimates
for Molecular Partners AG?

What are the Net Income projections
for Molecular Partners AG?

How accurate were the past Net Income estimates
for Molecular Partners AG?

What are the EPS projections
for Molecular Partners AG?

How accurate were the past EPS estimates
for Molecular Partners AG?

What are the EBIT projections
for Molecular Partners AG?

How accurate were the past EBIT estimates
for Molecular Partners AG?

Compare the revenue forecasts
for Molecular Partners AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Molecular Partners AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Molecular Partners AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Molecular Partners AG compared to its peers.

Compare the P/E ratios
of Molecular Partners AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Molecular Partners AG with its peers.

Analyze the financial leverage
of Molecular Partners AG compared to its main competitors.

Show all profitability ratios
for Molecular Partners AG.

Provide ROE
for Molecular Partners AG.

Provide ROA
for Molecular Partners AG.

Provide ROIC
for Molecular Partners AG.

Provide ROCE
for Molecular Partners AG.

Provide Gross Margin
for Molecular Partners AG.

Provide Operating Margin
for Molecular Partners AG.

Provide Net Margin
for Molecular Partners AG.

Provide FCF Margin
for Molecular Partners AG.

Show all solvency ratios
for Molecular Partners AG.

Provide D/E Ratio
for Molecular Partners AG.

Provide D/A Ratio
for Molecular Partners AG.

Provide Interest Coverage Ratio
for Molecular Partners AG.

Provide Altman Z-Score Ratio
for Molecular Partners AG.

Provide Quick Ratio
for Molecular Partners AG.

Provide Current Ratio
for Molecular Partners AG.

Provide Cash Ratio
for Molecular Partners AG.

What is the historical Revenue growth
over the last 5 years for Molecular Partners AG?

What is the historical Net Income growth
over the last 5 years for Molecular Partners AG?

What is the current Free Cash Flow
of Molecular Partners AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Molecular Partners AG.

MOLN

Balance Sheet

Other Long-Term Assets

Molecular Partners AG
Other Long-Term Assets

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

Adjust for Inflation

Molecular Partners AG
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

	Other Long-Term Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Molecular Partners AG SIX:MOLN	Other Long-Term Assets N/A	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
ADC Therapeutics SA NYSE:ADCT	Other Long-Term Assets $711k	CAGR 3-Years 21%	CAGR 5-Years 19%	CAGR 10-Years N/A
AC Immune SA NASDAQ:ACIU	Other Long-Term Assets N/A	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
CRISPR Therapeutics AG NASDAQ:CRSP	Other Long-Term Assets $27.4m	CAGR 3-Years 8%	CAGR 5-Years 43%	CAGR 10-Years N/A
Basilea Pharmaceutica AG SIX:BSLN	Other Long-Term Assets CHf13.8m	CAGR 3-Years 236%	CAGR 5-Years 62%	CAGR 10-Years 53%
Kuros Biosciences AG SIX:KURN	Other Long-Term Assets CHf209k	CAGR 3-Years -12%	CAGR 5-Years N/A	CAGR 10-Years N/A

No Stocks Found

Molecular Partners AG
Glance View

Market Cap

178.8m CHF

Industry

Biotechnology

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Open MOLN Analysis

MOLN Intrinsic Value

3.07 CHF

Overvaluation 37%

Intrinsic Value

Price

What is Intrinsic Value?

Molecular Partners AG
SIX:MOLN

Molecular Partners AG
Other Long-Term Assets

Molecular Partners AG
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Molecular Partners AG
Glance View

See Also

Company

Help

Tools

Stocks

Molecular Partners AG SIX:MOLN

Molecular Partners AG Other Long-Term Assets

Molecular Partners AG Other Long-Term Assets Peer Comparison

Competitors Analysis Latest Figures & CAGR of Competitors

Molecular Partners AG Glance View

See Also

Company

Help

Tools

Stocks

Molecular Partners AG
SIX:MOLN

Molecular Partners AG
Other Long-Term Assets

Molecular Partners AG
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Molecular Partners AG
Glance View